These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 10638040)

  • 21. The pharmacoeconomics of venlafaxine in depression.
    Morrow TJ
    Am J Manag Care; 2001 Sep; 7(11 Suppl):S386-92. PubMed ID: 11570029
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of the cost effectiveness of escitalopram versus venlafaxine XR in major depressive disorder.
    Fernandez JL; Montgomery S; Francois C
    Pharmacoeconomics; 2005; 23(2):155-67. PubMed ID: 15748090
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Successfully treated patients with vortioxetine versus venlafaxine: a simplified cost-effectiveness analysis based on a head-to-head study in Asian patients with major depressive disorder.
    Wang G; Zhao K; Reynaud-Mougin C; Loft H; Ren H; Eriksen HF; Ettrup A
    Curr Med Res Opin; 2020 May; 36(5):875-882. PubMed ID: 31990207
    [No Abstract]   [Full Text] [Related]  

  • 24. Adherence and Persistence Across Antidepressant Therapeutic Classes: A Retrospective Claims Analysis Among Insured US Patients with Major Depressive Disorder (MDD).
    Keyloun KR; Hansen RN; Hepp Z; Gillard P; Thase ME; Devine EB
    CNS Drugs; 2017 May; 31(5):421-432. PubMed ID: 28378157
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A model to evaluate the cost-effectiveness of oral therapies in the management of patients with major depressive disorders.
    Einarson TR; Arikian S; Sweeney S; Doyle J
    Clin Ther; 1995; 17(1):136-53. PubMed ID: 7758056
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Switching to sertraline or venlafaxine after failure of SSRIs treatment in major depressive disorder: an economic evaluation of the STAR*D trial.
    Leelahanaj T
    J Med Assoc Thai; 2012 May; 95 Suppl 5():S29-37. PubMed ID: 22934442
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of depression in the elderly: a review of the recent literature on the efficacy of single- versus dual-action antidepressants.
    Mukai Y; Tampi RR
    Clin Ther; 2009 May; 31(5):945-61. PubMed ID: 19539096
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Amygdala Reactivity to Emotional Faces in the Prediction of General and Medication-Specific Responses to Antidepressant Treatment in the Randomized iSPOT-D Trial.
    Williams LM; Korgaonkar MS; Song YC; Paton R; Eagles S; Goldstein-Piekarski A; Grieve SM; Harris AW; Usherwood T; Etkin A
    Neuropsychopharmacology; 2015 Sep; 40(10):2398-408. PubMed ID: 25824424
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Duloxetine: a review of its use in the treatment of major depressive disorder.
    Frampton JE; Plosker GL
    CNS Drugs; 2007; 21(7):581-609. PubMed ID: 17579500
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of efficacy and tolerability of reboxetine and venlafaxine XR in major depression and major depression with anxiety features: an open label study.
    Akkaya C; Sivrioglu EY; Akgoz S; Eker SS; Kirli S
    Hum Psychopharmacol; 2006 Jul; 21(5):337-45. PubMed ID: 16856215
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Child and adolescent depression: short-term treatment effectiveness and long-term opportunities.
    Ryan ND
    Int J Methods Psychiatr Res; 2003; 12(1):44-53. PubMed ID: 12830309
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: A 6-month randomized controlled trial.
    Gelenberg AJ; Lydiard RB; Rudolph RL; Aguiar L; Haskins JT; Salinas E
    JAMA; 2000 Jun; 283(23):3082-8. PubMed ID: 10865302
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Desvenlafaxine: another "me too" drug?
    Sopko MA; Ehret MJ; Grgas M
    Ann Pharmacother; 2008 Oct; 42(10):1439-46. PubMed ID: 18698015
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A randomized, double-blind comparison of duloxetine and venlafaxine in the treatment of patients with major depressive disorder.
    Perahia DG; Pritchett YL; Kajdasz DK; Bauer M; Jain R; Russell JM; Walker DJ; Spencer KA; Froud DM; Raskin J; Thase ME
    J Psychiatr Res; 2008 Jan; 42(1):22-34. PubMed ID: 17445831
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Venlafaxine XR demonstrates higher rates of sustained remission compared to fluoxetine, paroxetine or placebo.
    Shelton C; Entsuah R; Padmanabhan SK; Vinall PE
    Int Clin Psychopharmacol; 2005 Jul; 20(4):233-8. PubMed ID: 15933485
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A cost-effectiveness model of escitalopram, citalopram,and venlafaxine as first-line treatment for major depressive disorder in Belgium.
    Demyttenaere K; Hemels ME; Hudry J; Annemans L
    Clin Ther; 2005 Jan; 27(1):111-24. PubMed ID: 15763612
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative efficacy, acceptability, and safety of medicinal, cognitive-behavioral therapy, and placebo treatments for acute major depressive disorder in children and adolescents: a multiple-treatments meta-analysis.
    Ma D; Zhang Z; Zhang X; Li L
    Curr Med Res Opin; 2014 Jun; 30(6):971-95. PubMed ID: 24188102
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A systematic review of duloxetine and venlafaxine in major depression, including unpublished data.
    Schueler YB; Koesters M; Wieseler B; Grouven U; Kromp M; Kerekes MF; Kreis J; Kaiser T; Becker T; Weinmann S
    Acta Psychiatr Scand; 2011 Apr; 123(4):247-65. PubMed ID: 20831742
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment adherence and persistence with duloxetine, venlafaxine XR, and escitalopram among patients with major depressive disorder and chronic pain-related diseases.
    Wang J; Liu X; Mullins CD
    Curr Med Res Opin; 2011 Jul; 27(7):1303-13. PubMed ID: 21561393
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.